AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
26 Mar 2020 07:00 AM
RNS
Lokelma approved in Japan for hyperkalaemia
24 Mar 2020 04:41 PM
RNS
Second Price Monitoring Extn
24 Mar 2020 04:36 PM
RNS
Price Monitoring Extension
24 Mar 2020 12:02 PM
RNS
Price Monitoring Extension
23 Mar 2020 04:40 PM
RNS
Second Price Monitoring Extn
23 Mar 2020 04:36 PM
RNS
Price Monitoring Extension
23 Mar 2020 12:08 PM
RNS
Second Price Monitoring Extn
23 Mar 2020 12:03 PM
RNS
Price Monitoring Extension
20 Mar 2020 10:20 AM
RNS
Second Price Monitoring Extn
20 Mar 2020 10:15 AM
RNS
Price Monitoring Extension
20 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
19 Mar 2020 07:00 AM
RNS
Lynparza granted orphan drug designation in Japan
17 Mar 2020 07:00 AM
RNS
Imfinzi confirmed overall survival in CASPIAN
13 Mar 2020 04:35 PM
RNS
Price Monitoring Extension
12 Mar 2020 11:00 AM
RNS
Notice of AGM
12 Mar 2020 07:00 AM
RNS
Update on Phase III GY004 trial for cediranib
10 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
06 Mar 2020 07:00 AM
RNS
Update on Phase III DANUBE trial in bladder cancer
04 Mar 2020 07:00 AM
RNS
Filing of Form 20-F with SEC
03 Mar 2020 11:00 AM
RNS
Annual Financial Report
02 Mar 2020 03:00 PM
RNS
Total Voting Rights
02 Mar 2020 07:00 AM
RNS
Divestment of hypertension medicines completed
27 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
25 Feb 2020 07:00 AM
RNS
AstraZeneca divests global rights to Movantik
19 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
19 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
14 Feb 2020 07:00 AM
RNS
AZN: Full-year and Q4 2019 results
03 Feb 2020 03:00 PM
RNS
Total Voting Rights
27 Jan 2020 07:00 AM
RNS
Enhertu Phase II trial met primary endpoint
27 Jan 2020 07:00 AM
RNS
Brilinta met primary endpoint in stroke trial
27 Jan 2020 07:00 AM
RNS
AstraZeneca divests hypertension medicines
27 Jan 2020 07:00 AM
RNS
AstraZeneca to recover brazikumab (MEDI2070)
20 Jan 2020 07:00 AM
RNS
Imfinzi, tremelimumab granted ODD in liver cancer
20 Jan 2020 07:00 AM
RNS
FDA grants Lynparza Priority Review for PROfound
13 Jan 2020 07:01 AM
RNS
Lynparza granted FDA Priority Review for PAOLA-1
13 Jan 2020 07:00 AM
RNS
Update on Epanova Phase III STRENGTH trial
06 Jan 2020 07:01 AM
RNS
Farxiga granted FDA heart failure Priority Review
06 Jan 2020 07:00 AM
RNS
Lokelma approved in China for hyperkalaemia
02 Jan 2020 03:00 PM
RNS
Total Voting Rights
30 Dec 2019 07:00 AM
RNS
US FDA approved Lynparza for pancreatic cancer
23 Dec 2019 07:00 AM
RNS
Triple-combination approved in China for COPD
23 Dec 2019 07:00 AM
RNS
Enhertu (trastuzumab deruxtecan) approved in US
20 Dec 2019 07:00 AM
RNS
AstraZeneca divests rights to Arimidex and Casodex
17 Dec 2019 06:06 PM
RNS
FDA panel backs Lynparza use for pancreatic cancer
16 Dec 2019 07:00 AM
RNS
Seroquel rights agreement complete: Europe, Russia
12 Dec 2019 07:00 AM
RNS
Imfinzi approved in China for Stage III NSCLC
11 Dec 2019 01:00 PM
RNS
Trastuzumab deruxtecan achieves ORR of 60.9%
05 Dec 2019 07:00 AM
RNS
Lynparza approved in China for 1L BRCAm ovarian
03 Dec 2019 07:00 AM
RNS
AstraZeneca divests Seroquel rights: US and Canada
02 Dec 2019 03:00 PM
RNS
Total Voting Rights

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings